US Stock MarketDetailed Quotes

QLGN Qualigen Therapeutics

Watchlist
  • 0.4000
  • -0.0010-0.25%
Close Mar 27 16:00 ET
2.07MMarket Cap-107P/E (TTM)

About Qualigen Therapeutics Company

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Company Profile

SymbolQLGN
Company NameQualigen Therapeutics
Listing Date06/24/2015
Issue Price5.00
Founded2004
CEOMr. Michael S. Poirier
MarketNASDAQ
Employees38
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address2042 Corte Del Nogal
CityCarlsbad
ProvinceCalifornia
CountryUnited States of America
Zip Code92011
Phone1-760-918-9165

Company Executives

  • Name
  • Position
  • Salary
  • Michael S. Poirier
  • Chairman of the Board and Chief Executive Officer
  • 728.45K
  • Christopher L. Lotz
  • Vice President, Finance, Chief Financial Officer and Principal Accounting Officer
  • 194.00K
  • Sidney W Emery, Jr
  • Independent Director
  • 77.79K
  • Ira E. Ritter
  • Independent Director
  • 95.50K
  • Matthew Korenberg
  • Independent Director
  • 72.37K
  • Kurt H. Kruger
  • Independent Director
  • 69.66K
  • Richard A. David
  • Independent Director
  • 69.66K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg